Colgate-Palmolive (NYSE:CL – Get Free Report) had its price target dropped by equities researchers at JPMorgan Chase & Co. from $103.00 to $97.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 12.06% from the company’s previous close.
Several other research firms also recently weighed in on CL. StockNews.com downgraded shares of Colgate-Palmolive from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. Stifel Nicolaus dropped their price target on Colgate-Palmolive from $95.00 to $93.00 and set a “hold” rating on the stock in a research note on Monday. UBS Group reduced their price objective on Colgate-Palmolive from $104.00 to $100.00 and set a “buy” rating for the company in a research note on Monday. Morgan Stanley lowered their target price on Colgate-Palmolive from $111.00 to $104.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Wells Fargo & Company reduced their price target on shares of Colgate-Palmolive from $92.00 to $83.00 and set an “underweight” rating for the company in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Colgate-Palmolive presently has an average rating of “Hold” and a consensus target price of $101.16.
Read Our Latest Stock Analysis on Colgate-Palmolive
Colgate-Palmolive Stock Performance
Colgate-Palmolive (NYSE:CL – Get Free Report) last posted its quarterly earnings data on Friday, January 31st. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.01. Colgate-Palmolive had a net margin of 14.38% and a return on equity of 477.77%. During the same period last year, the company posted $0.87 EPS. Sell-side analysts forecast that Colgate-Palmolive will post 3.74 EPS for the current year.
Institutional Trading of Colgate-Palmolive
A number of large investors have recently added to or reduced their stakes in the stock. Centricity Wealth Management LLC purchased a new stake in shares of Colgate-Palmolive during the 4th quarter worth approximately $27,000. Union Bancaire Privee UBP SA bought a new position in Colgate-Palmolive during the fourth quarter valued at $32,000. Hager Investment Management Services LLC bought a new stake in shares of Colgate-Palmolive in the fourth quarter valued at $36,000. Reston Wealth Management LLC purchased a new position in shares of Colgate-Palmolive during the 3rd quarter valued at $42,000. Finally, Roxbury Financial LLC bought a new position in shares of Colgate-Palmolive during the 4th quarter worth $43,000. Hedge funds and other institutional investors own 80.41% of the company’s stock.
Colgate-Palmolive Company Profile
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
See Also
- Five stocks we like better than Colgate-Palmolive
- How to Evaluate a Stock Before Buying
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- What Are Trending Stocks? Trending Stocks Explained
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.